Brought to you by 
CABG Medical gets rights to Angiotech's cardiovascular IP
15 Apr 2005
Executive Summary
Angiotech (combines drugs, devices, and biomaterials to treat various diseases) has granted CABG Medical (coronary bypass surgery devices) exclusive rights to use its technology that treats restenosis and proliferative diseases with localized delivery of paclitaxel. CABG also gets access to Angiotech's related IP portfolio.
Deal Industry
- Biotechnology
- Medical Devices
-
Medical Devices
- Implantable Devices
- Surgical Equipment & Devices
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Includes Equity
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
CABG Medical gets rights to Angiotech's cardiovascular IP
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice